Elevated lipoprotein(a), or Lp(a), is a significant but often overlooked risk factor for cardiovascular disease, the leading cause of death globally. Unlike LDL cholesterol, Lp(a) levels are genetically determined and unaffected by lifestyle changes, making early detection crucial for at-risk individuals. The American Heart Association, with support from Novartis Pharmaceuticals Corporation, has launched the Lp(a) Community Health Centers Discovery Project to enhance awareness and screening for Lp(a) in community health centers across the U.S.
Dr. Kaavya Paruchuri, a volunteer with the American Heart Association, emphasizes the importance of a one-time Lp(a) test for individuals with a family history of heart disease or other risk factors. The project has already seen success in increasing Lp(a) testing at participating centers, with ten additional sites set to join this year. These efforts are part of a broader initiative to integrate Lp(a) screening into routine cardiovascular risk assessments, leveraging lessons from health systems that have already implemented such processes.
Research underscores the critical role of Lp(a) in increasing the risk for atherosclerotic cardiovascular disease-related events, including heart attacks and strokes. Despite limited treatment options for high Lp(a), identifying elevated levels can motivate individuals to adopt heart-healthy lifestyles and discuss potential interventions with their healthcare providers. The initiative also highlights the need for greater public and professional education on Lp(a), as current awareness levels remain low.
Community health centers interested in joining the Lp(a) Discovery Project can express their interest by completing a form available at heart.org/LpaDiscovery, with a deadline of August 15. This initiative represents a pivotal step toward mitigating cardiovascular disease risk through early detection and informed patient-provider discussions.
